|
시장보고서
상품코드
2077529
바이러스 벡터 및 플라스미드 DNA 검사 서비스 시장 : 서비스 유형별, 최종 사용자별, 지역별Viral Vector And Plasmid DNA Testing Services Market, By Service Type, By End User, and By Region |
||||||
바이러스 벡터 및 플라스미드 DNA 검사 서비스 시장은 2026년에 4억 6,670만 달러 규모가 될 것으로 추정되고 있어 2033년에 23억 5,310만 달러에 이를 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 26.0%로 성장할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 4억 6,670만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년까지 예측 기간 CAGR : | 26.00% | 2033년 시장 규모 예측 : | 23억 5,310만 달러 |
바이러스 벡터는 유전자 치료 분야에서 가장 효과적인 전략이므로, 바이러스 벡터를 활용한 의약품의 신속한 개발에는 검사 서비스가 필수적입니다. 바이러스 벡터의 특성 평가는 직교 분석법에서 매우 중요한 역할을 합니다. 제품의 안전성, 동정, 순도, 효능을 포함한 규제적 관점에서도 이러한 특성 평가는 매우 중요합니다. 현재 바이러스 벡터는 암, 신경학, 혈액학, 안과, 대사성 질환, 근육 질환 등 다양한 치료법을 위해 개발되어, 세계 시장에서 널리 받아들여지고 있는 다양한 바이러스 기반 의약품의 주요 전달 시스템으로 자리 잡고 있습니다. 제약 산업에서는 바이러스 기반 의약품의 수많은 개발을 통해 밝은 미래가 기대되고 있습니다.
시장 역학
다양한 치료 목적을 위한 바이러스 벡터 및 플라스미드 DNA와 관련된 현재 진행 중인 임상시험이 예측 기간 동안 시장 성장을 견인할 것으로 전망됩니다. 예를 들어, 2022년 10월, 임상 연구 기관인 ICON plc는 사우디아라비아에 본사를 둔 이맘 압둘라흐만 빈 파이살 대학교의 연구진들과 공동으로, 건강한 성인을 대상으로 한 COVID-19 예방용 pDNA 백신 후보의 2회 또는 3회 접종 요법에 대한 안전성과 면역원성을 평가하는 1상 임상시험의 시작을 발표했습니다. 이 pDNA 백신 후보는 건강한 성인(18-55세)을 대상으로 근육 내(IM) 투여를 통해 접종됩니다.
이와 마찬가지로, 2022년 1월에는 생명공학 기업인 GeneOne Life Science, Inc.가 또 다른 생명공학 기업인 Inovio Pharmaceuticals와 공동으로 GLS-5700의 안전성, 내약성 및 면역원성을 평가하기 위한 임상시험을 시작한다고 발표했습니다. GLS-5700은 지카바이러스에 대한 합성 DNA 플라스미드 백신으로, 현재 1상 임상시험 단계에 있습니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트도 제공합니다.
- 본 조사에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로, 전 세계 바이러스 벡터 및 플라스미드 DNA 검사 서비스 시장의 주요 기업 프로파일을 발표하고 있습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있게 됩니다.
- '세계 바이러스 벡터 및 플라스미드 DNA 검사 서비스 시장 보고서'는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 바이러스 벡터 및 플라스미드 DNA 검사 서비스 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 원활하게 의사결정을 내릴 수 있습니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 바이러스 벡터 및 플라스미드 DNA 검사 서비스 시장 : 서비스 유형별, 2021-2033년
제5장 세계의 바이러스 벡터 및 플라스미드 DNA 검사 서비스 시장 : 최종 사용자별, 2021-2033년
제6장 세계의 바이러스 벡터 및 플라스미드 DNA 검사 서비스 시장 : 지역별, 2021-2033년
제7장 경쟁 구도
제8장 섹션
JHS 26.07.13Viral Vector And Plasmid Dna Testing Services Market is estimated to be valued at USD 466.7 Mn in 2026 and is expected to reach USD 2,353.1 Mn by 2033, growing at a compound annual growth rate (CAGR) of 26.0% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 466.7 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 26.00% | 2033 Value Projection: | USD 2,353.1 Mn |
Testing services are crucial for the timely development of viral vector-based medicines since viral vectors are the best strategy for gene therapies. Characterization of the viral vector plays an essential role for orthogonal analytical methods. Through the regulatory prospective which includes product safety, identification, purity, and potency, the characterization is significant. These days, viral vectors are the primary delivery system for a variety of virus-based medications that have been created for various therapies for conditions including cancer, neurology, hematology, ophthalmology, metabolic or muscular disorders and are accepted on the global market. The pharmaceutical industry has a bright future for several developments based on viral-based medicines.
Market Dynamics
The ongoing clinical trials on the viral vectors and plasmid DNA for various treatment is expected to fuel growth of the market in the forecast period. For instance, in October, 2022, ICON plc, a clinical research organization, in collaboration with researchers from Imam Abdulrahman Bin Faisal University, based in Saudi Arabia, announced the initiation of Phase-I clinical trial Study to Evaluate the Safety and Immunogenicity of 2 or 3 dose regimen of investigational Prophylactic pDNA Vaccine Candidate Against COVID-19 in Healthy Adults. The pDNA vaccine candidate is administered intramuscularly (IM) by immunizing healthy adults (18-55 years).
Similarly, in January 2022, GeneOne Life Science, Inc., a biotechnology company, in collaboration with Inovio Pharmaceuticals, a biotechnology company, announced initiation of clinical trial to assess the safety, tolerability, and immunogenicity of GLS-5700. GLS-5700 is a synthetic DNA plasmid vaccine against the Zika virus, which is currently in Phase -1.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global viral vector and plasmid DNA testing services market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study are Charles River Laboratories, Inc., WuXi AppTec Co., Ltd., Cobra Biologics and Pharmaceutical Services, Merck KgaA, Lonza, Eurofins Scientific, FinVector Vision Therapies, Advanced Bioscience Laboratories, Inc., Takara Bio Inc., ViruSure GmbH, Genezen Laboratories, Akron Biotech., Catalent, Inc, AcuraBio., CATUG Biotechnology., Creative Biogene and Aldevron
- Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global viral vector and plasmid DNA testing services market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global viral vector and plasmid DNA testing services market
Detailed Segmentation:
- Global Viral Vector and Plasmid DNA Testing Services Market, By Service Type (Revenue, USD Mn, 2021 - 2033)
- Safety
- Genetic Characterization
- Purity
- Identity
- Potency
- Global Viral Vector and Plasmid DNA Testing Services Market By End User:
- Pharmaceutical and Biotechnology Industries
- Research Organizations
- Global Viral Vector and Plasmid DNA Testing Services Market, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Charles River Laboratories, Inc.
- WuXi AppTec Co., Ltd.
- Cobra Biologics and Pharmaceutical Services
- Merck KgaA
- Lonza
- Eurofins Scientific
- FinVector Vision Therapies
- Advanced Bioscience Laboratories, Inc.
- Takara Bio Inc.
- ViruSure GmbH
- Genezen Laboratories
- Akron Biotech.
- Catalent, Inc
- AcuraBio
- CATUG Biotechnology.
- Creative Biogene.
- Aldevron
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Service Type
- Market Snapshot, By End User
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Attractiveness Analysis
- Market Opportunities
- Merger, Acquisition, Collaborations
- Funding and Investment
- Future Prospective of Viral vector and plasma DNA testing
- Regulatory Guideline and Compliances
- Key Developments
- PEST Analysis
- PORTER's Analysis
4. Global Viral Vector and Plasmid DNA Testing Services Market, By Service Type, 2021-2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Safety
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Genetic Characterization
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Purity
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Identity
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Potency
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
5. Global Viral Vector and Plasmid DNA Testing Services Market, By End User, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segments Trends
- Pharmaceutical and Biotechnology Industries
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Research Organizations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
6. Global Viral Vector and Plasmid DNA Testing Services Market, By Region, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Million)
- North Africa
- Central Africa
- South Africa
7. Competitive Landscape
- Charles River Laboratories, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- WuXi AppTec Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Cobra Biologics and Pharmaceutical Services
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Merck KgaA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Lonza
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eurofins Scientific
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- FinVector Vision Therapies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Advanced Bioscience Laboratories, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Takara Bio Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- ViruSure GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Genezen Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Akron Biotech.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Catalent, Inc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AcuraBio.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- CATUG Biotechnology.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Creative Biogene.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Aldevron
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
8. Section
- Research Methodology
- About Us
